MedTrace Logo

LENS - Long-term Eltrombopag Observational Study

NCT00643929 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 164

Last updated 2017-03-23

No results posted yet for this study

Summary

A long term observational ocular safety study in adults who have received study medication (either active drug or placebo) in a phase II or III clinical study evaluating eltrombopag. The study will follow subjects for 2.5 years following their last ocular assessment on their prior treatment study (regardless of the therapeutic indication) and will describe long-term ocular safety with respect to changes in the lenses over time from all subjects.

Conditions

  • Purpura, Thrombocytopaenic, Idiopathic

Interventions

DRUG

Eltrombopag

Subjects participated in a prior eltrombopag study, having received either eltrombopag or placebo

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • United States
  • Australia
  • Bulgaria
  • Canada
  • Czechia
  • France
  • Germany
  • Hong Kong
  • Hungary
  • India
  • Italy
  • Pakistan
  • Peru
  • Poland
  • Puerto Rico
  • Russia
  • Spain
  • Sweden
  • Tunisia
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00643929 on ClinicalTrials.gov